The present disclosure relates to photoplethysmograph signals from a pulse oximeter and particularly, to a method for objectively determining patient stress from a photoplethysmograph signal.
Often, patients experience stress when in a caregiver facility or when receiving care at home. For example, the patient may experience stress due to medical procedures, medications, or length of stay at a facility, to name a few stress inducers. Generally, it is very subjective to determine a patient's stress level. However, to properly manage care, the caregiver must be aware of the patient's stress levels. It is desirable to determine a patient's stress level without subjecting the patient to additional tests, procedures, or medical equipment. That is, it is desirable to determine the patient's stress level with existing equipment that is being used to monitor the patient. It is also desirable to objectively quantify a level of the patient's stress. By quantifying stress, the caregiver may provide more accurate care to the patient.
The present disclosure includes one or more of the features recited in the appended claims and/or the following features which, alone or in any combination, may comprise patentable subject matter.
According to an aspect of the disclosed embodiments, a method of determining a stress level of a patient from a photoplethysmograph signal may include acquiring a photoplethysmograph signal from a pulse oximeter. The method may also include detecting peaks and valleys in the photoplethysmograph signal to determine a heart rate variability waveform. The method may also include detrending the heart rate variability waveform to determine a detrended waveform. The method may also include normalizing the detrended waveform to determine a normalized waveform. The method may also include determining a dominant frequency of the normalized waveform. The method may also include determining a coherence index of the heart rate variability waveform based on the dominant frequency.
It may be contemplated that the coherence index is between 0 and 1. A smoothness of the heart rate variability waveform may indicate a stress level of a patient.
In some embodiments, a dominant frequency within a range of 0.04 to 0.15 Hz may indicate a combination of sympathetic nervous system influence and parasympathetic nervous system influence. A dominant frequency within a range of 0.15 to 0.4 Hz may indicate parasympathetic nervous system activity. The coherence index may be a ratio of dominant frequencies within a range of 0.04 to 0.15 Hz to dominant frequencies within a range of 0.15 to 0.4 Hz.
Optionally, the method may include sampling at least one minute of the photoplethysmograph signal. The method may also include detecting peaks and valleys in the photoplethysmograph signal further comprises performing a peak to peak detection algorithm on a sample of the photoplethysmograph signal. The method may also include determining a coherence index further comprises deriving a normalized correlation index of the heart rate variability waveform with a sine waveform having the dominant frequency. The method may also include determining a coherence index further comprises multiplying the sine waveform having the dominant frequency with the heart rate variability waveform. The method may also include resampling the photoplethysmograph signal to acquire uniform heart rate variability waveforms.
According to another aspect of the disclosed embodiments, a stress level monitoring system may include a controller and a pulse oximeter electrically coupled to the controller. The pulse oximeter may measure a photoplethysmograph signal. The controller may determine a stress level of a patient from the photoplethysmograph signal by acquiring a photoplethysmograph signal from a pulse oximeter. The controller may also detect peaks and valleys in the photoplethysmograph signal to determine a heart rate variability waveform. The controller may also detrend the heart rate variability waveform to determine a detrended waveform. The controller may also normalize the detrended waveform to determine a normalized waveform. The controller may also determine a dominant frequency of the normalized waveform. The controller may also determine a coherence index of the heart rate variability waveform based on the dominant frequency.
It may be contemplated that the coherence index is between 0 and 1. A smoothness of the heart rate variability waveform may indicate a stress level of a patient.
In some embodiments, a dominant frequency within a range of 0.04 to 0.15 Hz may indicate a combination of sympathetic nervous system influence and parasympathetic nervous system influence. A dominant frequency within a range of 0.15 to 0.4 Hz may indicate parasympathetic nervous system activity. The coherence index may be a ratio of dominant frequencies within a range of 0.04 to 0.15 Hz to dominant frequencies within a range of 0.15 to 0.4 Hz.
Optionally, the controller may sample at least one minute of the photoplethysmograph signal. The controller may perform a peak to peak detection algorithm on a sample of the photoplethysmograph signal. The controller may derive a normalized correlation index of the heart rate variability waveform with a sine waveform having the dominant frequency. The controller may multiply the sine waveform having the dominant frequency with the heart rate variability waveform. The controller may resample the photoplethysmograph signal to acquire uniform heart rate variability waveforms.
According to yet another aspect of the disclosed embodiments, a method of determining a stress level of a patient from a photoplethysmograph signal includes acquiring a photoplethysmograph signal from a pulse oximeter. The method may also include calculating a heart rate waveform from the photoplethysmograph signal. The method may also include determining a dominant frequency of the heart rate waveform. The method may also include generating a sine wave from the dominant frequency. The method may also include determining a coherence index of the heart rate waveform by multiplying the heart rate waveform by the sine wave.
In some embodiments, the coherence index may be between 0 and 1. A smoothness of the heart rate waveform may indicate a stress level of a patient. A dominant frequency within a range of 0.04 to 0.15 Hz may indicate a combination of sympathetic nervous system influence and parasympathetic nervous system influence. A dominant frequency within a range of 0.15 to 0.4 Hz may indicate parasympathetic nervous system influence. The coherence index may be a ratio of dominant frequencies within a range of 0.04 to 0.15 Hz to dominant frequencies within a range of 0.15 to 0.4 Hz.
Optionally, the method includes sampling at least one minute of the photoplethysmograph signal. The method may also include resampling the photoplethysmograph signal to acquire uniform heart rate variability waveforms.
Additional features, which alone or in combination with any other feature(s), such as those listed above and/or those listed in the claims, can comprise patentable subject matter and will become apparent to those skilled in the art upon consideration of the following detailed description of various embodiments exemplifying the best mode of carrying out the embodiments as presently perceived.
The detailed description particularly refers to the accompanying figures in which:
While the concepts of the present disclosure are susceptible to various modifications and alternative forms, specific exemplary embodiments thereof have been shown by way of example in the drawings and will herein be described in detail. It should be understood, however, that there is no intent to limit the concepts of the present disclosure to the particular forms disclosed, but on the contrary, the intention is to cover all modifications, equivalents, and alternatives falling within the spirit and scope of the invention as defined by the appended claims.
Generally, a patient's level of stress can be subjectively measured based on a heart rate variability of the patient. For example, referring to
Also seen in
Further information regarding the patient's stress can be derived from a Fourier Transform of the heart rate waveform. For example, by taking a Fast Fourier Transform of the heart rate waveform, additional information regarding stress levels can be subjectively obtained.
Accordingly, based on the heart rate variability, as seen in
Referring to
At block 220 of the method 200, peak and valley detection is performed on the filtered signal 210 to identify the peaks 212 and valleys 214 of the signal 210. The peaks 212 and valleys 214 can be graphed, as shown in the graph 222 of
Once uniform sampling is achieved, at block 250, the waveform 252 of graph 232 is de-trended and normalized. That is, shifted and scaled versions of the data are created with the intention is that the normalized values allow the comparison of corresponding normalized values for different datasets in a way that eliminates the effects of certain gross influences, as in an anomaly time series. Some types of normalization involve only a rescaling to arrive at values relative to some size variable.
At block 260, the heart rate waveform 262, as illustrated in
Accordingly, a photoplethysmograph signal can be utilized to provide various information regarding the patient. First, the photoplethysmograph signal is indicative of the oxygen saturation of the patient. Second, the photoplethysmograph signal can be converted to determine a heart rate variation of the patient. Third, subjective information regarding stress levels can be derived from the heart rate waveform of the patient and a Fast Fourier Transform of the heart rate waveform. Lastly, a quantifiable objective score can be given to the patient's stress levels.
Heart rate variability is the patient's heart response to the central nervous system, which can measure the activation of the patient's autonomic nervous systems. Heart rate variability is a variation of heart beat-to-beat intervals, which can be extracted from a photoplethysmograph signal. The beat-to-beat intervals can be derived by using the peak detection algorithm. The coherence index is derived from the similarity of heart rate variability waveform with a pure sinusoidal wave by using a correlation analysis. The coherence index measures the heart rhythm coherence (sine wave-like rhythmic pattern) which implies the increased parasympathetic activity. The lower the index, the higher the stress condition is. As such, an objective score to provide the patient's stress condition is provided.
The system and method described herein require almost no additional when using an existing vital signs monitor and only additional software modification is required. The system and method described herein are non-invasive, portable, and suitable for homecare.
Referring to
The pulse oximeter 302 is electrically coupled to the controller 304 via a cable 310. In some embodiments, the cable 310 includes a universal serial bus (USB) connector that is configured to connect to a USB port (not shown) provided on the controller 304. The pulse oximeter 302 provides a non-invasive method for monitoring a patient's oxygen saturation (SO2) through a finger monitor 312 that is positioned on the patient's finger. In some embodiments, the pulse oximeter provides data related to the patient's peripheral oxygen saturation (SpO2). In other embodiments, a monitor may be provided to measure the patient's arterial oxygen saturation (SaO2) from arterial blood gas analysis. In some embodiments, the pulse oximeter 302 may be coupled to the patient's earlobe, foot, or any other thin part of the patient's body. The pulse oximeter 302 passes two wavelengths of light through the body part to a photodetector. The pulse oximeter 302 measures the changing absorbance at each of the wavelengths, allowing the pulse oximeter 302 to determine absorbency due to the pulsing arterial blood alone, excluding venous blood, skin, bone, muscle, and fat.
The pulse oximeter 302 is operable to detect data related to the patient's SpO2 and heart rate. The pulse oximeter 302 also detects a photoplethysmograph signal (PPG) of the patient. The data acquired by the pulse oximeter 302 is transmitted to the controller 304. The controller 304 may display the data on the graphical user interface 316. The controller 304 is also operable to use the data to determine a heart rate variation waveform related to the patient's respiratory rate. While it may be known to acquire heart rate variation waveforms from raw PPG data, the methods described herein provide unique steps and data manipulation that are not currently applied to raw PPG data. As a result, the methods described herein represent an improvement over known methods for acquiring variation waveforms.
Any theory, mechanism of operation, proof, or finding stated herein is meant to further enhance understanding of principles of the present disclosure and is not intended to make the present disclosure in any way dependent upon such theory, mechanism of operation, illustrative embodiment, proof, or finding. It should be understood that while the use of the word preferable, preferably or preferred in the description above indicates that the feature so described can be more desirable, it nonetheless cannot be necessary and embodiments lacking the same can be contemplated as within the scope of the disclosure, that scope being defined by the claims that follow.
In reading the claims it is intended that when words such as “a,” “an,” “at least one,” “at least a portion” are used there is no intention to limit the claim to only one item unless specifically stated to the contrary in the claim. When the language “at least a portion” and/or “a portion” is used the item can include a portion and/or the entire item unless specifically stated to the contrary.
It should be understood that only selected embodiments have been shown and described and that all possible alternatives, modifications, aspects, combinations, principles, variations, and equivalents that come within the spirit of the disclosure as defined herein or by any of the following claims are desired to be protected. While embodiments of the disclosure have been illustrated and described in detail in the drawings and foregoing description, the same are to be considered as illustrative and not intended to be exhaustive or to limit the disclosure to the precise forms disclosed. Additional alternatives, modifications and variations can be apparent to those skilled in the art. Also, while multiple inventive aspects and principles can have been presented, they need not be utilized in combination, and many combinations of aspects and principles are possible in light of the various embodiments provided above.
This application claims priority under 35 U.S.C. § 119(e) to U.S. Provisional Patent Application Ser. No. 62/669,444, filed May 10, 2018, and titled “SYSTEM AND METHOD TO DETERMINE HEART RATE VARIABILITY COHERENCE INDEX,” which is expressly incorporated by reference herein.
Number | Date | Country | |
---|---|---|---|
62669444 | May 2018 | US |